measurable residual disease in aml
Published 6 years ago • 57 plays • Length 4:30Download video MP4
Download video MP3
Similar videos
-
2:18
the utility of measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)
-
1:02
challenges with measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)
-
2:35
mrd focus: why measurable residual disease testing is the future
-
5:33
clinical utility of the homologous recombination deficiency score in aml & mds
-
1:34:29
aml'de flt3 mutasyonları ve ötesi. klinik uygulamalarımızda genetik nerede?
-
13:00
challenges in mrd measurement by multiparameter flow cytometry in aml
-
3:47
current and emerging treatment options for lr-mds-associated anemia following esa failure
-
3:10
novel aml treament approaches
-
1:36
the synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating aml
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
1:02
the impact of sequencing in aml
-
1:11
are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
-
4:22
the role of mrd in aml
-
1:49
bringing precision medicine and mrd into clinical strategies
-
2:25
novel ai model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
-
3:30
know aml | measurable residual disease
-
2:25
analyzing aml: novel therapies in review
-
0:55
the role of rna modifications in mds and aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:18
the impact of secondary aml mutations on the prognosis of patients with npm1-mutated aml
-
3:02
highlights in aml and mds from eha 2022